Gene Therapy Shows Lasting Benefit for Children With Rare Disorder

MedPage Today) — For children born with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), an investigational gene therapy showed sustained clinical efficacy and safety at a median follow-up of 7.5 years.
Among…